Stockscreener 앱 받기
3.02
3.07%
0.09
시간 외 거래:
3.02
전일 마감가:
$2.93
열려 있는:
$2.94
하루 거래량:
10,477
Relative Volume:
0.40
시가총액:
$2.59M
수익:
-
순이익/손실:
$-9.29M
주가수익비율:
-0.9956
EPS:
-3.0332
순현금흐름:
$-9.42M
1주 성능:
+1.34%
1개월 성능:
-21.56%
6개월 성능:
-20.32%
1년 성능:
-49.66%
1일 변동 폭
$2.94
$3.1227
1주일 범위
$2.70
$3.5733
52주 변동 폭
$2.23
$8.92
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
명칭
Scinai Immunotherapeutics Ltd Adr
전화
972-8-9302529
주소
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
SCNI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| SCNI | 3.02 | 2.59M | 0 | -9.29M | -9.42M | -3.0332 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Scinai Immunotherapeutics Ltd Adr 주식(SCNI)의 최신 뉴스
Scinai Regains Full Compliance with Nasdaq Listing Requirements - Benzinga
Scinai secures $2 million investment commitment By Investing.com - Investing.com India
Today's Market - InvestorPlace
Taking on analysts’ expectations and winning: Scinai Immunotherapeutics Ltd ADR (SCNI) - SETE News
Scinai reports promising psoriasis treatment study - Investing.com
Heather Campe, Sr. VP at Fuller H B Co, sells shares worth over $1.9m By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR Inc. (SCNI) Price Performance: The Role of Supply and Demand - The InvestChronicle
Scinai reports promising psoriasis treatment study By Investing.com - Investing.com
Baird lowers Lululemon shares target on mixed U.S. traffic and spending By Investing.com - Investing.com India
Scinai Immunotherapeutics gets Nasdaq compliance extension By Investing.com - Investing.com
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR (SCNI-Q) QuotePress Release - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) to Present at Europe Dermatology Drug Development Summit - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Receive $900K Grant for CDMO Business Unit - The Globe and Mail
Sezzle Inc. ex-director sells over $33,000 in company stock By Investing.com - Investing.com
Ambit Capital sets Buy rating on Mahindra & Mahindra shares By Investing.com - Investing.com India
Sunrise New Energy unveils new battery anode material By Investing.com - Investing.com
Bank lifts XPeng stock rating to neutral By Investing.com - Investing.com
BridgeBio shares set for quick recovery post HELIOS-B results - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Showcasing Services at Upcoming BIO-Europe Spring 2024 - The Globe and Mail
Nvidia CFO Colette Kress sells shares worth over $12 million By Investing.com - Investing.com
BeiGene COO Wu Xiaobin sells over $500k in company stock - Investing.com
Scinai Immunotherapeutics (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023 - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Releases FY 2023 Financial Results - The Globe and Mail
Check out these key findings about Scinai Immunotherapeutics Ltd ADR (SCNI) – Sete News - SETE News
Scinai Immunotherapeutics (NASDAQ: SCNI) Enters Agreement for Exercise of Outstanding Warrants - The Globe and Mail
Scinai Immunotherapeutics (NASDAQ: SCNI) Releases Status Report on NASDAQ Compliance - The Globe and Mail
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Investing.com UK
Scinai Immunotherapeutics (NASDAQ: SCNI) to Showcase CDMO Services at Premier CPHI Barcelona Event - The Globe and Mail
Should investors be concerned about SCNI’s high price-to-sales ratio? - US Post News
Scinai Immunotherapeutics (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana Pharma - The Globe and Mail
Scinai Immunotherapeutics Ltd ADR’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
Scinai receives EIB terms for loan-to-equity conversion By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR (SCNI) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Atlassian co-CEO Cannon-Brookes sells over $1.29 million in company stock By Investing.com - Investing.com
Scinai Immunotherapeutics Ltd ADR Inc. (SCNI) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Scinai regains Nasdaq compliance, eyes EIB loan conversion By Investing.com - Investing.com
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session ... - Investing.com UK
Doris Matsui invests over $1 million in Intrinsic Exchange Group By Investing.com - Investing.com
Dream Finders Homes CEO sells over $960k in company stock By Investing.com - Investing.com
UBS cuts Cielo SA stock target, downgrades to neutral By Investing.com - Investing.com
Quarterly Metrics: Quick and Current Ratios for Scinai Immunotherapeutics Ltd ADR (SCNI) – DWinneX - The Dwinnex
Scinai faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com
Paramount and Charter extend distribution deal By Investing.com - Investing.com
Scinai Immunotherapeutics Showcases Growth and InnovationTipRanks.com - TipRanks
Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update - Marketscreener.com
Scinai Immunotherapeutics Battles Nasdaq Delisting - TipRanks
Scinai Immunotherapeutics enacts reverse split to meet Nasdaq rules - Investing.com
Biotech Rips Following Five-Year Master Service Agreement Release - The Globe and Mail
SMFL Stock Quote Price and Forecast - CNN
Scinai Immunotherapeutics Ltd Adr (SCNI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):